PMA PHARMACEUTICAL OUTCOMES PLANNING INCLUDES EFFORT TO ADDRESS MEASUREMENT OF "DISADVANTAGED CONDITIONS": SEPTEMBER MEETING WILL REVIEW ASSESSMENT TOOLS
The Pharmaceutical Manufacturers Association is preparing to evaluate current performance measures that could be used as the foundation for a system to assess the quality of pharmaceutical care. Approximately 50-70 individuals suggested by PMA member companies are expected to participate in a Sept. 8-9 meeting in Washington, D.C. on the status of current measurement tools. The meeting will be the second this year held by the association to anticipate developments in the field of outcomes assessment and to try to ensure that the methods adopted in the future account for pharmaceutical treatments.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth